MicroRNA alterations in neuropathologic cognitive disorders with an emphasis on dementia: Lessons from animal models

Abstract Cognitive dysfunction is a state of losing or having difficulties in remembering, learning, focusing, or making decisions that impact individual healthy life. Small single‐stranded and nonprotein coding RNAs, microRNAs (miRNAs) participate actively in regulatory processes, incorporate cognitive signaling pathways, and intensely affect cognitive evolution. miRNAs exert their modification activities through translational or transcriptional processes. Reportedly, cognitive impairment and dementia are rising, especially in developing countries. Herein we provided a brief review of original studies addressing miRNA changes in the most common neurological diseases with a focus on dementia and Alzheimer's disease. It must be noted that an increase in the level of certain miRNAs but a decrease in other ones deteriorate cognitive performance. The current review revealed that induction of miR‐214‐3p, miR‐302, miR‐21, miR‐ 200b/c, miR‐207, miR‐132, miR‐188‐3p and 5p, and miR‐873 improved cognitive impairment in various cognitive tasks. On the other hand, intentionally lowering the level of miR‐34a, miR‐124, miR‐574, and miR‐191a enhanced cognitive function and memory. Synaptic dysfunction is a core cause of cognitive dysfunction; miRNA‐34, miRNA‐34‐c, miRNA‐124, miRNA‐188‐5p, miRNA‐210‐5p, miRNA‐335‐3p, and miRNA‐134 strongly influence synaptic‐related mechanisms. The downregulation of miRNA‐132 aggregates both amyloid and tau in tauopathy. Concerning the massive burden of neurological diseases worldwide, the future challenge is the translation of animal model knowledge into the detection of pathophysiological stages of neurocognitive disorders and designing efficient therapeutic strategies. While the delivery procedure of agomir or antagomir miRNAs into the brain is invasive and only applied in animal studies, finding a safe and specific delivery route is a priority.